SCHEMBL3081772

SCHEMBL3081772

CC(C)CN(C)C(=O)c1nc(N)nc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.49
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
NUDT1 P36639 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
APP P05067 1/20 0.43
ITK Q08881 1/20 0.42
ELANE P08246 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
DCPS Q96C86 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087920 0.85 ADORA3 (0.52) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL16628740 0.83 ADORA3 (0.50) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL3081057 0.83 CYP3A4 (0.53) ADORA3
SCHEMBL3096062 0.83 ADORA3 (0.50) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL13144843 0.83 HSP90AA1 (0.36) ADORA3HSP90AA1HSP90AB1NUDT1ITK
SCHEMBL3086774 0.82 ADORA3 (0.52) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL3075153 0.82 ADORA3 (0.57) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL3088200 0.82 NUDT1 (0.53) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL3094124 0.81 ADORA3 (0.48) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1
SCHEMBL3097104 0.81 ADORA3 (0.48) ADORA3HSP90AA1HSP90AB1NUDT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164833-B1 Quinazolinamide derivatives useful for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2015-04-15 EP claimed
US-8501754-B2 Quinazolinamide derivatives MERCK PATENT GMBH (DE) 2013-08-06 US claimed
US-20100234324-A1 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-16 US claimed
EP-2164833-B1 Quinazolinamide derivatives useful for the treatment of tumour diseases MERCK PATENT GMBH (DE) 2015-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234324-A1 Quinazolinamide derivatives HSP90AB1, HSP90AA1, HSP90AB2P ADORA3 3301/4885HSP90AA1 2/4885HSP90AB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.